Inventiva S.A. Reports on Subscription Agreements
Ticker: IVEVF · Form: 6-K · Filed: Dec 16, 2024 · CIK: 1756594
| Field | Detail |
|---|---|
| Company | Inventiva S.A. (IVEVF) |
| Form Type | 6-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, securities
TL;DR
Inventiva S.A. confirms ongoing subscription agreements for shares/warrants, previously announced.
AI Summary
Inventiva S.A. is filing a Form 6-K for December 2024, reporting on the entry into subscription agreements with certain investors. These agreements, previously disclosed on October 15, 2024, involve the issuance and sale of ordinary shares or pre-funded warrants to purchase ordinary shares.
Why It Matters
This filing provides an update on the company's financing activities, which could impact its capital structure and future operational capacity.
Risk Assessment
Risk Level: low — The filing is a routine update on previously disclosed financing agreements and does not introduce new material risks.
Key Players & Entities
- Inventiva S.A. (company) — Registrant
- October 15, 2024 (date) — Date of previous disclosure
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed to report on the entry into subscription agreements with certain investors, as previously disclosed.
When were these subscription agreements initially reported?
The subscription agreements were previously reported in a Form 6-K filed on October 15, 2024.
What is Inventiva S.A. agreeing to issue under these agreements?
Inventiva S.A. agreed to issue and sell ordinary shares or, in lieu thereof, pre-funded warrants to purchase ordinary shares.
What is the nominal value of the ordinary shares being issued?
The nominal value of the ordinary shares is €0.01 per share.
What is the principal executive office address of Inventiva S.A.?
The principal executive office is located at 50 rue de Dijon, 21121 Daix, France.
Filing Stats: 1,871 words · 7 min read · ~6 pages · Grade level 17.1 · Accepted 2024-12-16 16:13:13
Filing Documents
- tm2431159d1_6k.htm (6-K) — 25KB
- tm2431159d1_ex99-1.htm (EX-99.1) — 251KB
- tm2431159d1_ex99-2.htm (EX-99.2) — 119KB
- tm2431159d1_ex99-1img001.jpg (GRAPHIC) — 11KB
- 0001104659-24-128902.txt ( ) — 410KB
Forward-Looking Statements
Forward-Looking Statements This Report of Foreign Private Issuer on Form 6-K contains “forward-looking other than statements of historical facts, included in this Form 6-K are forward-looking statements. These statements include, but are not limited to, the timing and completion of the Multi-Tranche Financing; the anticipated proceeds from the Multi-Tranche Financing and the Company’s expected use of such proceeds; the satisfaction, in part or full of the conditions precedent to the issuance of the T1 bis Securities and the remaining securities issuable pursuant to the Multi-Tranche Financing; and the Company’s expectations with respect to its clinical trials, including NATiV3. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management’s beliefs. These that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inventiva S.A. Date: December 16, 2024 By: /s/ Frédéric Cren Name Frédéric Cren Title: Chief Executive Officer